The stocks for both Swiss and Israeli biotechs were up over 20% after the companies signed a merger agreement.

Vertex is approaching two key PDUFA dates in January for new treatments in cystic fibrosis and pain respectively.

Nektar has signed a definitive agreement to divest its Huntsville facility and associated reagent supply business to ...

Novo Nordisk and Ascendis Pharma have agreed to collaborate in developing metabolic and cardiovascular therapies, among them ...

The first programme in the partnership involves the creation of an ‘early warning system’ for future pandemics. Credit: ...

Increasingly, injectable manufacturers recognise that to achieve maximum profitability, they need to focus on the value they ...

Polling by the site FiveThirtyEight on 3 November had current Vice President Kamala Harris with a less than 1% lead over ...

Disc Medicine has announced a US Food and Drug Administration (FDA) agreement on the regulatory path for its investigational ...

The US FDA has granted fast track designation to FELIQS’ lead product FLQ-101 for preventing retinopathy of prematurity (ROP) ...

Researchers from Northwestern and Case Western Reserve universities have developed a polymer therapeutic to treat ...

GlaxoSmithKline (GSK) has agreed to acquire Chimagen Biosciences’ CMG1A46, a clinical-stage therapy designed to target B cell ...

UK-based biopharmaceutical company Prokarium has received two Notices of Allowance from the US Patent and Trademark Office.